OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 [Yahoo! Finance]
OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219
OnKure Therapeutics (NASDAQ: OKUR) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
OnKure Therapeutics (NASDAQ: OKUR) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $33.00 price target on the stock.
OnKure Announces New Date for Upcoming Investor Call [Yahoo! Finance]